PD-L1 CPS als Förderschwelle für ICI bei metastasiertem Ösophagealkrebs. Esophag...
Deterministische Ansicht der Quelle YAML Entität. Klinische Autorität bleibt mit den zitierten Quell-IDs und Rezensenten Sign-off Zustand.
| ID | BMA-PDL1-CPS-ESOPHAGEAL |
|---|---|
| Art | Therapeutische Relevanz |
| Status | reviewed 2026-05-07 | actionability review required |
| Erkrankungen | DIS-ESOPHAGEAL |
| Quellen | SRC-ESMO-ESOPHAGEAL-2024 SRC-NCCN-ESOPHAGEAL-2025 |
Fakten zur Handlungsfähigkeit
| Biomarker | BIO-PDL1-CPS |
|---|---|
| Erkrankung | DIS-ESOPHAGEAL |
| ESCAT-Stufe | IA |
| Empfohlene Kombinationen | pembrolizumab + cisplatin + fluoropyrimidine (CPS≥10 SCC 1L per SRC-NCCN-ESOPHAGEAL-2025), pembrolizumab monotherapy (CPS≥10 SCC/adeno 2L per SRC-NCCN-ESOPHAGEAL-2025) |
| Zusammenfassung der Beweise | PD-L1 CPS used as eligibility threshold for ICI in metastatic esophageal cancer. Esophageal SCC: CPS ≥10 — pembrolizumab + cisplatin + fluoropyrimidine 1L (KEYNOTE-590), and pembrolizumab monotherapy 2L (KEYNOTE-181 CPS≥10 subgroup). Esophageal adeno and GEJ: same CPS criteria as gastric adeno (NCCN 2025 treats GEJ adeno with gastric algorithm). Testing by IHC 22C3 pharmDx mandatory. Threshold-gated indication selection is performed by the algorithm layer (IND-ESOPH-METASTATIC-2L-PEMBRO-CPS10); this BMA entry surfaces ESCAT tier context only. |
Anmerkungen
Variant_qualifier null — threshold gating (CPS≥10) enforced by indication layer. KEYNOTE-590 and KEYNOTE-181 source stubs not yet ingested; citing NCCN/ESMO as proxies until trial source backfill PRs add them.
Verwendet von
Keine Rückverweise im YAML-Korpus gefunden.